BioLine Rx (BioLine Rx) 3-Year Book Growth Rate : -42.30% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is BioLine Rx 3-Year Book Growth Rate?

BioLine Rx's Book Value per Share for the quarter that ended in Dec. 2023 was $0.13.

During the past 12 months, BioLine Rx's average Book Value per Share Growth Rate was -78.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -42.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was -44.00% per year. During the past 10 years, the average Book Value per Share Growth Rate was -31.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of BioLine Rx was 8.20% per year. The lowest was -50.00% per year. And the median was -28.65% per year.

Competitive Comparison of BioLine Rx's 3-Year Book Growth Rate

For the Biotechnology subindustry, BioLine Rx's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where BioLine Rx's 3-Year Book Growth Rate falls into.

BioLine Rx 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

BioLine Rx (OTCPK:BLNEF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

BioLine Rx 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of BioLine Rx's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (OTCPK:BLNEF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

BLRX:USA BLRX:Israel YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.